{{NoteTA|G1=Medicine}}
{{medical}}

{{drugbox
| Verifiedfields = changed
| verifiedrevid = 470474859
| IUPAC_name = ''N''-(2-diethylaminoethyl)-5-[(''Z'')-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1''H''-pyrrole-3-carboxamide
| image = Sunitinib.svg
| image2 = Sunitinib-3D-balls.png

<!--Clinical data-->
| tradename = 索坦
| Drugs.com = {{drugs.com|monograph|sutent}}
| MedlinePlus = a607052
| licence_EU = Sutent
| licence_US = Sunitinib
| pregnancy_AU = D
| pregnancy_US = D
| legal_US = Rx-only
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| bioavailability = 不受食物影响
| protein_bound = 95%
| metabolism = [[肝脏|肝脏]] ([[CYP3A4|CYP3A4]]参与代谢)
| elimination_half-life = 40至60小时（舒尼替尼）<br />80至110小时（代谢产物）
| excretion = 61% 粪便；16% 肾脏

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 
| ATC_prefix = L01
| ATC_suffix = XE04<!--will become available on January 2007-->
| PubChem = 5329102
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01268
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4486264
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = V99T50803M
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06402
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 38940
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 535

<!--Chemical data-->
| C=22 | H=27 | F=1 | N=4 | O=2 
| molecular_weight = 398.474 g/mol<br />532.561 g/mol ([[malate|malate]])
| smiles = CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C
| InChI = 1/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
| InChIKey = WINHZLLDWRZWRT-ATVHPVEEBZ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WINHZLLDWRZWRT-ATVHPVEESA-N
}}

'''舒尼替尼'''（由[[辉瑞|辉瑞]]研发，商标名'''索坦'''）是一种口服的小分子多靶点[[受体酪氨酸激酶|受体酪氨酸激酶]]抑制剂，2006年1月26日被[[FDA|FDA]]批准用于治疗对标准疗法没有响应或不能耐受的[[胃肠道基质肿瘤|胃肠道基质肿瘤]]和转移性[[肾细胞癌|肾细胞癌]]。舒尼替尼是第一种被批准用于同时治疗两种类型[[癌症|癌症]]的药物。<ref name="FDA"/>

==药理==
舒尼替尼通过靶向多个受体酪氨酸激酶来抑制细胞信号。

这些[[受体|受体]]包括：血小板衍化生长因子R链（PDGF-R）和[[血管内皮生长因子|血管内皮生长因子]]受体（VEGFRs），它们在肿瘤的[[血管生成|血管生成]]和细胞增殖中扮演重要角色。这些同时进行的抑制促使肿瘤血管化减少并使癌症发生[[细胞凋亡|细胞凋亡]]，最终使肿瘤萎缩。

舒尼替尼同样抑制KIT基因（[[CD117|CD117]]），<ref name="pmid19015436"/>，当突变使其不适当地激活时，是一种导致大多数胃肠道基质肿瘤的受体酪氨酸激酶。<ref>{{cite journal | doi = 10.1016/j.hoc.2008.11.006 | pmid = 19248971 | volume=23 | issue=1 | title=Gastrointestinal stromal tumor: a clinical overview | journal=Hematol. Oncol. Clin. North Am. | pages=69–78, viii|date=February 2009}}</ref>它作为二线疗法被推荐用于KIT基因突变的肿瘤病人，这些人可能对[[伊马替尼|伊马替尼]]抗药，或是服药耐受性降低。<ref>{{cite journal | doi = 10.1586/era.09.34 | pmid = 19496720 | volume=9 | issue=6 | title=Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations | journal=Expert Rev Anticancer Ther | pages=831–8|date=June 2009}}</ref><ref>{{cite journal | doi = 10.1517/13543780902980171 | pmid = 19453268 | volume=18 | issue=6 | title=Sunitinib in solid tumors | journal=Expert Opin Investig Drugs | pages=821–34|date=June 2009}}</ref>

另外，舒尼替尼抑制其它受体酪氨酸激酶<ref name="PI"/>，包括：
* [[RET原癌基因|RET]]
* [[粒细胞集落刺激因子|CSF-1R]]
* [[CD135|flt3]]

由于舒尼替尼针对许多不同受体，它也带来很多副作用，例如[[手足病|手足病]]、[[口腔炎|口腔炎]]和其它皮肤性中毒。

==参考资料==
{{reflist|2|refs=

<ref name="FDA">{{cite web | author = 美国食品药品监督管理局 | title = FDA approves new treatment for gastrointestinal and kidney cancer | url=http://www.fda.gov/bbs/topics/news/2006/NEW01302.html |year=2006 | authorlink = Food and Drug Administration}}</ref>

<ref name="PI">{{cite journal | title = Prescribing information for Sutent (sunitinib malate) | journal = [[Pfizer|Pfizer, Inc, New York NY]]}}</ref>

<ref name="pmid19015436">{{cite journal |author=Hartmann JT, Kanz L |title=Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition |journal=Arch Dermatol |volume=144 |issue=11 |pages=1525–6 |pmid=19015436 |doi=10.1001/archderm.144.11.1525 |url=http://archderm.ama-assn.org/cgi/pmidlookup?view=long&pmid=19015436 |date=November 2008 |deadurl=yes |archiveurl=http://archive.wikiwix.com/cache/20110702015230/http://archderm.ama-assn.org/cgi/pmidlookup?view=long&pmid=19015436 |archivedate=2011-07-02 }}</ref>

}}
{{Extracellular chemotherapeutic agents}}

[[Category:輝瑞產品|Category:輝瑞產品]]